Lilly’s Alzheimer’s EXPEDITION3 Proves Positive For Biogen’s Anti-Amyloid At CTAD
Executive Summary
Lilly’s Phase III EXPEDITION3 results for solanezumab at CTAD contribute data to the Alzheimer’s field about the role of amyloid in disease progression, including the effect that other amyloid-targeting antibodies may have in ongoing clinical trials, such as Biogen’s Phase III candidate aducanumab.
You may also be interested in...
Lecanemab Set A New Bar In Alzheimer’s, Now Many Drugs Are Seeking To Raise It
Drug makers are more enthusiastic than ever about the outlook for developing drugs for Alzheimer's. Scrip reports back on the latest developments at CTAD.
Another Nail In Amyloid Hypothesis Coffin? Merck Ends Pivotal BACE Inhibitor Study
In another blow for the amyloid hypothesis in Alzheimer's disease, Merck ended its pivotal EPOCH study for the BACE inhibitor verubecestat based on an interim assessment that there was "virtually no chance of finding a positive clinical effect" in the nearly completed Phase II/III clinical trial.
Alzheimer’s Update: Amyloid Hypothesis Lives On At Biogen, Lilly, Merck, Pfizer, Roche
Biogen rose and fell based on the company’s latest aducanumab results, but the Clinical Trials on Alzheimer’s Disease meeting Dec. 8-10 showed that regardless of Lilly’s Phase III solanezumab failure, companies continue to invest in amyloid and other hypotheses, including BACE, gamma secretase and other programs.